|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
| Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma |
| Arlene Siefker-Radtke, MD |
| Sam Chang engages with Arlene Siefker-Radtke to explore the transformative impact of erdafitinib in treating advanced and metastatic urothelial cancer. Dr. Siefker-Radtke illuminates the targeted approach of erdafitinib, emphasizing its efficacy in hitting specific genetic alterations, particularly FGFR3/2 mutations, prevalent in 15-20% of metastatic bladder tumors. |
|
|
|
|
|
|
|
|
|
|
|
|
BOND-003 Trial Results in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
|
Mark Tyson II, MD, MPH
|
| Zachary Klaassen hosts Mark Tyson to discuss the BOND-003 trial evaluating cretostimogene for BCG-unresponsive NMIBC. This study examines the mechanism by which this oncolytic immunotherapy selectively targets cancer cells by exploiting Rb pathway deficiencies and enhancing tumor-specific immunity through GM-CSF expression.
|
|
|
|
|
|
|
|
|
|
|
|
| Advancing mHSPC Treatment Options: ARANOTE Trial Analysis |
Fred Saad, MD, FRCS, and Neal Shore, MD, FACS
Fred Saad and Neal Shore discuss the ARANOTE trial with Zach Klaassen, exploring the use of darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's diverse patient population and impressive results, including a 46% reduction in radiographic progression-free survival risk. |
|
|
|
|
|
|
|
|
|
|
| PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results |
| Tanya Dorff, MD |
| Tanya Dorff discusses her team's Phase 1 trial on PSCA CAR T cell therapy for metastatic castration-resistant prostate cancer, published in Nature Medicine. Dr. Dorff highlights that prostate cancer's immunosuppressive environment poses significant challenges, making the development of potent therapies like CAR T cells crucial. |
|
|
|
|
|
|
|
|
|
|
|
|
KEYNOTE-564 Shows Overall Survival Benefit in Kidney Cancer with Pembrolizumab
|
|
Toni K. Choueiri, MD
|
| Alicia Morgans interviews Toni Choueiri about the results of the KEYNOTE-564 trial, marking a significant milestone in kidney cancer treatment with pembrolizumab showing an overall survival benefit as an adjuvant therapy. Dr. Choueiri highlights the trial's inclusion criteria, focusing on patients at some risk of recurrence post-surgery with clear cell RCC.
|
|
|
|
|
|
|
|
|
|
|
|
| Characterization of Complete Responders to Nivolumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone and Patients with Lymph Node–Only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial
|
| Matt Galsky, MD, FASCO
|
| Matt Galsky presents a post hoc analysis from the CheckMate 901 trial, which showed that patients with lymph node-only mUC who received nivolumab plus gemcitabine-cisplatin (GC) had significantly improved OS and PFS compared to those receiving GC alone. Notably, among complete responders, over half had lymph node-only mUC, and nivolumab+GC led to durable disease control, with a higher complete response rate and longer treatment-free intervals. These findings support nivolumab plus GC as a potential standard first-line treatment for mUC.
|
|
|
|
|
|
| A New Horizon in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Anktiva (N-803) + BCG
|
| Zachary Klaassen, MD, MSc
|
| The QUILT-3.032 trial demonstrated that the combination of N-803 (Anktiva) and BCG significantly improved response rates in patients with BCG-unresponsive NMIBC, with a 71% complete response rate at 3 months in Cohort A, and a median duration of response of 26.6 months. Based on these results, the FDA approved N-803 + BCG in April 2024 for this patient group, marking a major advancement in treatment options for BCG-unresponsive NMIBC. Ongoing trials, including QUILT-2.005 in BCG-naïve patients, are further evaluating the combination's potential, with expanding global access through partnerships to address BCG shortages.
|
|
|
|
|
|
| Efficacy of Talazoparib and Enzalutamide in mCRPC Patients Previously Treated with Androgen Receptor Pathway Inhibitors or Docetaxel – Post Hoc Analysis from Both Cohorts in TALAPRO-2 Study |
| Neeraj Agarwal, MD, FASCO |
| Neeraj Agarwal presented a post hoc analysis from the TALAPRO-2 study, evaluating the efficacy of talazoparib plus enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors or docetaxel. The analysis included patients from both the all-comers population and those with homologous recombination repair gene alterations. The combination of talazoparib and enzalutamide showed a 37% reduction in the risk of radiological progression in the all-comers population and a 55% reduction in the HRR-deficient population. |
|
|
|
|
|
|
|
|
|
|
| Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell RCC |
| Brian I. Rini, MD, FASCO |
| Brian Rini presents the final analysis of the phase 3 LITESPARK-005 study, comparing belzutifan to everolimus in previously treated advanced clear cell RCC. Belzutifan demonstrated significant progression-free survival (PFS) and objective response rate (ORR) benefits over everolimus, with a median PFS of 5.6 months versus 5.6 months, and a higher 12- and 24-month PFS rate. However, no significant improvement in overall survival was observed, and while belzutifan showed a longer duration of therapy and fewer discontinuations due to adverse events, the safety profile was similar between the two treatments. |
|
|
|
|
|
| Subcutaneous Nivolumab vs Intravenous Nivolumab in Patients with Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Updated Efficacy and Safety Results from CheckMate 67T
|
| Laurence Albiges, MD, PhD
|
| Laurence Albiges presents updated results from the CheckMate 67T study, comparing subcutaneous (SC) versus intravenous (IV) nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma. The study found that Nivolumab SC was non-inferior to Nivolumab IV in terms of overall response rate (ORR) and progression-free survival (PFS), with no new safety concerns identified after 15 months of follow-up.
|
|
|
|
|
|
| Should I Order a PET Scan? Integrating Molecular Imaging into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities
|
| Marc Bjurlin, DO, MSc, FACOS
|
| Marc Bjurlin discusses integrating molecular imaging into urologic oncology, emphasizing its evolving role in diagnosing and managing prostate, renal, bladder, and germ cell cancers. He highlighted the significant impact of PSMA PET in prostate cancer, improving detection and patient care, and the potential of molecular imaging to differentiate renal tumor histologies. Dr. Bjurlin also explored the use of PET/CT in bladder cancer staging and germ cell tumor management, noting emerging challenges and the need for further research in predicting responses to immunotherapy and chemotherapy.
|
|
|
|
|
|
|
|
|
|
|
|
|
